Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

DA”) or European Medicines Agency
(“EMEA”);
• the safety and efficacy of the Company’s products or product candidates;
• the Company’s assessment of its clinical trials;
• the commencement and completion of clinical trials;
• the Company’s ability to develop, manufacture, license and sell its products or product
candidates;
• the Company’s ability to enter into and successfully execute license and collaborative
agreements, if any;
• the adequacy of the Company’s capital resources and cash flow projections, and the
Company’s ability to obtain sufficient financing to maintain the Company’s planned
operations;
• the adequacy of the Company’s patents and proprietary rights;
• the impact of litigation that has been brought against the Company and its officers and
directors and any proposed settlement of such litigation;
• the Company’s ability to regain compliance with the NASDAQ’s listing qualifications, or
its ability to successfully appeal the NASDAQ delisting; and
• the other risks described under Certain Risks and Uncertainties Related to the
Company’s Business, as contained in the Company’s Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a
number of factors that could cause actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the Company's Annual Report on Form
10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:
For Genta Incorporated
Tara Spiess/Andrea Romstad
TS Communications Group, LLC
(908) 286-3980
info@genta.c
'"/>





Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/22/2014)...   Long Beach dentist , Dr. Rassouli, is now ... standard in tooth replacement because they offer the closest match ... restore and preserve smiles and improve overall dental health. Dr. ... or as a part of a smile makeover or full ... a smile. The loss of a tooth can ...
(Date:11/22/2014)... 21, 2014 Many power shifts are ... influence of patients in the biopharmaceutical market is ... more than ever, understanding how to effectively acquire, ... is essential. According to recent ... companies spent about two-thirds of their patient-focused dollars ...
(Date:11/21/2014)... , Nov. 21, 2014 In September ... Performance Scrubs carried out a new product development plan ... very first "limited edition" lab coat , aptly ... professors of surgery in the world. The new women,s ... unisex predecessors, with a sleek envelope collar, vertical princess ...
Breaking Medicine Technology:Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2
... Sept. 19 A new topical lotion that,penetrates ... serious skin,infections, but without being systemically absorbed, has ... patients with onychomycosis, or,toenail fungus, a new study ... clinical trial are important to the fields of,dermatology ...
... Targanta,s Novel Drug Discovery Platform, CHICAGO, Sept. ... from two studies highlighting the in vitro,activity and ... osteomyelitis,models. Results are being presented today at the ... (ICAAC) taking place in,Chicago, IL and represent the ...
Cached Medicine Technology:New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 2New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 3Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models 2Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models 3
(Date:11/22/2014)... (PRWEB) November 22, 2014 Hastings and ... decades of experience announces providing clients with the option ... firm offers clients a flexible, intuitive and easy to ... with having access to Google + allows clients to ... to make a more informed decision when retaining an ...
(Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
(Date:11/22/2014)... Aliso Viejo, California (PRWEB) November 22, 2014 ... have announced a new plugin entitled FCPX 3D Model bringing ... , “FCPX 3D Model allows users to add obj files ... of Pixel Film Studios. “Blurring the line between professional and ... FCPX3D Model from Pixel Film Studios allows Final Cut Pro ...
(Date:11/22/2014)... Wright & Schulte LLC reports that six ... been scheduled between October 2016 and April 2017 in ... District Judge Matthew F. Kennelly, who is overseeing the ... on November 6, 2014 that outlined the trial schedule ... and other activities in preparation for the bellwether jury ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... Assam and Tripura have warned people against eating fish// ... saying the long time taken in transit rendered the ... ,The warning follows a report by the ... husks gets contaminated during the eight to 10 day ...
... Medical Journal report says that staff shortages in radiotherapy units ... and thus reducing their chances of surviving the condition. ... those in most developed countries and indeed many poorer countries," ... BMJ report. "Unfortunately the here and now of this is ...
... Ontario Government to launch a programme to ensure provision ... assault, who might have been exposed to the HIV/AIDS ... ($1,200) has resulted in a limited availability of this ... ,Very little effort is being done to promote ...
... the Health Minister of the Indian State of Bihar has announced ... introduced// in the state. An annual premium of Rs 250 will ... This will serve to provide the family with free health services ... the poverty line will receive the benefits without having to pay ...
... therapy is being provided to people who wish to give ... are over the age of 18 years// will benefit from ... Treatment for Ontario Patients (STOP) Study, which will also provide ... to which quitting method is more effective, according to Center ...
... transfer technology to generic drug manufacturers in the ... versions of the HIV drug saquinavir. ... Roche has announced further expansion of its current ... Developed Countries by providing local manufacturers with the ...
Cached Medicine News:Health News:Reach Of The Morning-After Pill Treatment Inadequate Among Sexual Assault Victims 2Health News:Roche offers HIV drug expertise to poor nations 2
Replacement bulb for Vibratome light system....
Injector blades come ten to an injector and allow for the easy replacement of Vibratome cutting blades....
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi...
... The Deluxe specimen bath mounts inside the ... bath allows for the separation of buffer and ... The bath can be sterilized and has round ... mounting specimens. The disks and bath surface ...
Medicine Products: